KR102747096B1 - 심한 변비를 치료하기 위한 조성물 및 방법 - Google Patents

심한 변비를 치료하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR102747096B1
KR102747096B1 KR1020207029661A KR20207029661A KR102747096B1 KR 102747096 B1 KR102747096 B1 KR 102747096B1 KR 1020207029661 A KR1020207029661 A KR 1020207029661A KR 20207029661 A KR20207029661 A KR 20207029661A KR 102747096 B1 KR102747096 B1 KR 102747096B1
Authority
KR
South Korea
Prior art keywords
constipation
pharmaceutical composition
dgat1
subject
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207029661A
Other languages
English (en)
Korean (ko)
Other versions
KR20200136428A (ko
Inventor
브라이언 케이. 허버드
마이클 에이치. 세라노-우
Original Assignee
앤지 파마수티컬스 잉크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 앤지 파마수티컬스 잉크. filed Critical 앤지 파마수티컬스 잉크.
Publication of KR20200136428A publication Critical patent/KR20200136428A/ko
Application granted granted Critical
Publication of KR102747096B1 publication Critical patent/KR102747096B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020207029661A 2018-03-16 2019-03-15 심한 변비를 치료하기 위한 조성물 및 방법 Active KR102747096B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862644033P 2018-03-16 2018-03-16
US62/644,033 2018-03-16
PCT/US2019/022499 WO2019178492A1 (en) 2018-03-16 2019-03-15 Compositions and methods for treating severe constipation

Publications (2)

Publication Number Publication Date
KR20200136428A KR20200136428A (ko) 2020-12-07
KR102747096B1 true KR102747096B1 (ko) 2024-12-26

Family

ID=67904819

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207029661A Active KR102747096B1 (ko) 2018-03-16 2019-03-15 심한 변비를 치료하기 위한 조성물 및 방법

Country Status (24)

Country Link
US (4) US11224590B2 (cg-RX-API-DMAC7.html)
EP (1) EP3765012B1 (cg-RX-API-DMAC7.html)
JP (1) JP7527984B2 (cg-RX-API-DMAC7.html)
KR (1) KR102747096B1 (cg-RX-API-DMAC7.html)
CN (1) CN111936137B (cg-RX-API-DMAC7.html)
AU (1) AU2019234956B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020018790A2 (cg-RX-API-DMAC7.html)
DK (1) DK3765012T3 (cg-RX-API-DMAC7.html)
EA (1) EA202092190A1 (cg-RX-API-DMAC7.html)
ES (1) ES3069001T3 (cg-RX-API-DMAC7.html)
FI (1) FI3765012T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20260544T1 (cg-RX-API-DMAC7.html)
IL (1) IL277332B2 (cg-RX-API-DMAC7.html)
LT (1) LT3765012T (cg-RX-API-DMAC7.html)
MX (1) MX2020009604A (cg-RX-API-DMAC7.html)
MY (1) MY205335A (cg-RX-API-DMAC7.html)
PE (1) PE20210158A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020551468A1 (cg-RX-API-DMAC7.html)
PL (1) PL3765012T3 (cg-RX-API-DMAC7.html)
PT (1) PT3765012T (cg-RX-API-DMAC7.html)
SG (1) SG11202008971VA (cg-RX-API-DMAC7.html)
SI (1) SI3765012T1 (cg-RX-API-DMAC7.html)
TW (1) TWI704917B (cg-RX-API-DMAC7.html)
WO (1) WO2019178492A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20210158A1 (es) 2018-03-16 2021-01-26 Anji Pharmaceuticals Inc Composiciones y metodos para tratar el estrenimiento grave
KR102989262B1 (ko) 2020-10-21 2026-07-08 주식회사 엘지에너지솔루션 전극 탭 고정부를 포함하는 용접장치 및 이를 이용한 전극 탭 용접 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013130370A2 (en) 2012-03-01 2013-09-06 Merck Sharp & Dohme Corp. Compounds as dgat-1 inhibitors

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3225997A (en) 1996-05-30 1998-01-05 Trustees Of Columbia University In The City Of New York, The Dna encoding acylcoenzyme a: cholesterol acyltransferase and uses thereof
US20030167483A1 (en) 1998-06-24 2003-09-04 Farese Robert V. Diacylglycerol O-acyltransferase
CA2330363C (en) 1998-06-24 2009-10-20 The Regents Of The University Of California Diacylglycerol o-acyltransferase
US6344548B1 (en) 1998-06-24 2002-02-05 The Regents Of The University Of California Diacylglycerol o-acyltransferase
US20030154504A1 (en) 1998-06-24 2003-08-14 Farese Robert V. Methods and compositions for modulating carbohydrate metabolism
US6100077A (en) 1998-10-01 2000-08-08 The Trustees Of Columbia University In The City Of New York Isolation of a gene encoding diacylglycerol acyltransferase
WO2002002551A1 (en) 2000-06-30 2002-01-10 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
US6444427B1 (en) 2000-07-11 2002-09-03 The Regents Of The University Of California Polymorphisms in a diacylglycerol acyltransferase gene, and methods of use thereof
JP4164645B2 (ja) 2002-08-09 2008-10-15 株式会社大塚製薬工場 Dgat阻害剤
EP1562956A4 (en) 2002-11-22 2007-10-10 Japan Tobacco Inc HETEROCYCLES CONTAINING FUSED BICYCLIC NITROGEN
US20040185559A1 (en) 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
AR044152A1 (es) 2003-05-09 2005-08-24 Bayer Corp Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
WO2005013907A2 (en) 2003-08-07 2005-02-17 Japan Tobacco Inc. Pyrrolo[1,2-b]pyridazine derivatives
GB0325192D0 (en) 2003-10-29 2003-12-03 Astrazeneca Ab Method of use
JP2005206492A (ja) 2004-01-21 2005-08-04 Sankyo Co Ltd スルホンアミド化合物
AU2005209115A1 (en) 2004-01-30 2005-08-11 Japan Tobacco Inc. Anorectic compounds
CA2572874A1 (en) 2004-07-02 2006-01-12 Sankyo Company Limited Urea derivative
JP2006045209A (ja) 2004-07-02 2006-02-16 Sankyo Co Ltd ウレア誘導体
WO2006019020A1 (ja) 2004-08-16 2006-02-23 Sankyo Company, Limited 置換されたウレア化合物
AU2005295453A1 (en) 2004-10-15 2006-04-27 Bayer Healthcare Llc Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
BRPI0519058A2 (pt) 2004-12-14 2008-12-23 Astrazeneca Ab composto ou um sal prà-droga farmaceuticamente aceitÁvel do mesmo, mÉtodos para produzir uma inibiÇço da atividade de dgat1 e para tratar diabete melito e/ou obesidade em um animal de sangue quente, uso de um composto, composiÇço farmacÊutica, e, processo para preparar um composto
MX2007013049A (es) 2005-04-19 2008-01-11 Bayer Pharmaceuticals Corp Preparacion y uso de derivados de aril alquil acido para el tratamiento de la obesidad.
WO2007002740A2 (en) 2005-06-28 2007-01-04 E. I. Du Pont De Nemours And Company Buffer compositions
PT2402319T (pt) * 2006-03-31 2017-12-11 Novartis Ag Inibidores de dgat
GB0611506D0 (en) 2006-06-10 2006-07-19 Astrazeneca Ab Chemical compounds
JO2972B1 (en) * 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
WO2009112445A1 (en) * 2008-03-10 2009-09-17 Novartis Ag Method of increasing cellular phosphatidyl choline by dgat1 inhibition
US8324241B2 (en) 2008-04-11 2012-12-04 Bristol-Myers Squibb Company Triazolo compounds useful as DGAT1 inhibitors
SG183529A1 (en) * 2010-03-30 2012-10-30 Novartis Ag Uses of dgat1 inhibitors
JP5841994B2 (ja) * 2010-04-08 2016-01-13 メディシノヴァ, インコーポレイテッド. 過敏性腸症候群の処置方法及びその治療用組成物
AR083417A1 (es) * 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
WO2013169648A1 (en) * 2012-05-07 2013-11-14 Novartis Ag Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug
BR112015004165A2 (pt) * 2012-08-29 2017-07-04 Salix Pharmaceuticals Inc métodos e composições laxantes para o tratamento de constipação e condições e doenças gastrointestinais relacionadas
CA2932873A1 (en) * 2014-01-09 2015-07-16 Sanofi Stabilized pharmaceutical formulations of insulin aspart
PE20210158A1 (es) 2018-03-16 2021-01-26 Anji Pharmaceuticals Inc Composiciones y metodos para tratar el estrenimiento grave

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013130370A2 (en) 2012-03-01 2013-09-06 Merck Sharp & Dohme Corp. Compounds as dgat-1 inhibitors

Also Published As

Publication number Publication date
IL277332A (en) 2020-10-29
US20240293376A1 (en) 2024-09-05
WO2019178492A1 (en) 2019-09-19
US11819495B2 (en) 2023-11-21
SI3765012T1 (sl) 2026-06-30
US20190282549A1 (en) 2019-09-19
LT3765012T (lt) 2026-05-25
TW201944995A (zh) 2019-12-01
BR112020018790A2 (pt) 2020-10-13
IL277332B2 (en) 2025-01-01
FI3765012T3 (fi) 2026-04-17
CA3093970A1 (en) 2019-09-19
PT3765012T (pt) 2026-04-27
EP3765012B1 (en) 2026-03-04
ES3069001T3 (en) 2026-06-03
CN111936137B (zh) 2023-09-08
MY205335A (en) 2024-10-16
PH12020551468A1 (en) 2021-09-01
US20220193044A1 (en) 2022-06-23
EP3765012A4 (en) 2021-12-15
US20260000651A1 (en) 2026-01-01
MX2020009604A (es) 2023-01-25
SG11202008971VA (en) 2020-10-29
TWI704917B (zh) 2020-09-21
AU2019234956A1 (en) 2020-10-01
US11224590B2 (en) 2022-01-18
PL3765012T3 (pl) 2026-06-01
JP7527984B2 (ja) 2024-08-05
US12343334B2 (en) 2025-07-01
PE20210158A1 (es) 2021-01-26
DK3765012T3 (da) 2026-04-27
AU2019234956B2 (en) 2025-01-30
EA202092190A1 (ru) 2020-11-19
KR20200136428A (ko) 2020-12-07
JP2021518431A (ja) 2021-08-02
IL277332B1 (en) 2024-09-01
HRP20260544T1 (hr) 2026-07-17
EP3765012A1 (en) 2021-01-20
CN111936137A (zh) 2020-11-13

Similar Documents

Publication Publication Date Title
US20260000651A1 (en) Compositions and methods for treating severe constipation
EP2582683B1 (en) Treatment of gout and hyperuricemia
CN106999475B (zh) 异噁唑啉化合物用于治疗蠕形螨病的用途
JP2017061512A (ja) 液体配合剤
TW202011965A (zh) 嗜中性球彈性蛋白酶抑制劑在肝病中之用途
JP2012500800A (ja) 神経因性疼痛の治療法
AU2021336289A9 (en) Ionic liquid formulations for treating diabetes
CA3093970C (en) Compositions and methods for treating severe constipation
CN117695277B (zh) 苯丙酸类似物的光学异构体组合物治疗或预防代谢紊乱中的用途
US9682033B2 (en) Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
US20250051273A1 (en) Glucose and Lipid Metabolism Regulating Agents, Pharmaceutical Compositions Comprising the Same, and Treatment Methods
CN116236477A (zh) 溶血磷脂酸受体5拮抗剂在制备心脏保护药物中的应用
TW202610632A (zh) 抗過量給藥的組合物及其用途
TW201701885A (zh) 改善腎臟病患者之腎臟功能和/或心臟功能的方法
JP2011032267A (ja) 11βHSD1阻害剤およびその用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20201015

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220222

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240808

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20241010

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20241223

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20241223

End annual number: 3

Start annual number: 1

PG1601 Publication of registration